Robert Cavorsi
Corporate Officer/Principal at ORGANOGENESIS HOLDINGS INC.
Net worth: 131 237 $ as of 29/04/2024
Profile
Robert Cavorsi is currently the Vice President-Strategy at Organogenesis Holdings, Inc. He previously worked as the Neurology Director-Sales Operations at Sumitomo Pharma America, Inc. from 2015 to 2016.
He obtained his undergraduate degree from The Pennsylvania State University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
18/04/2024 | 57,434 ( 0.04% ) | 131 237 $ | 29/04/2024 |
Robert Cavorsi active positions
Companies | Position | Start |
---|---|---|
ORGANOGENESIS HOLDINGS INC. | Corporate Officer/Principal | 31/12/2020 |
Former positions of Robert Cavorsi
Companies | Position | End |
---|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Sales & Marketing | 31/12/2015 |
Training of Robert Cavorsi
The Pennsylvania State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ORGANOGENESIS HOLDINGS INC. | Health Technology |
Private companies | 1 |
---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
- Stock Market
- Insiders
- Robert Cavorsi